Mycomeia - urine diagnostic for aspergillosis - aspergillosis causes morbidity and death in medically immune compromised patients, especially after cancer chemotherapy and transplant
Ended Project Grant Awarded Last action
- Award ID
- R44AI157572
- Recipient
-
Pearl Diagnostics, Inc. UEI N9CGVFYJM1B5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,929,728
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Funding
-
- $1,953,152.00 Federal
- $976,576.00 Non-federal
- Place of performance
- Baltimore, MD 21205, USA
Award details come from USAspending.gov.
Description
Recently, we have witnessed increased cases of influenza-associated aspergillosis and covid-19-associated aspergillosis, complicating effective treatment in those critically ILL with viral infections. Outcomes are poor in part because we lack sensitive diagnostic tests that are easy to use during high-risk periods. During our efforts to develop easier diagnostic tests, we discovered that fungal galactofuranose (galf)- containing antigens are excreted in urine of infected animals and people, using novel monoclonal antibodies. We engineered a prototype enzyme immunoassay called mycomeia, and performance was tested using urine samples obtained from patients with suspected and confirmed IA. Results showed >80% sensitivity and specificity, meeting predefined metrics for clinical study. As part of this proposal, this design-locked assay will move into clinical study, in three clinical microbiology laboratories to support FDA 510K application. Additional work is proposed to understand how the urine assay can be optimized to detect aspergillosis in non-hematology patients at risk, including ICU patients with covid-19. Success in meeting the milestones described will lead to commercial availability of the first rapid, easy to use urine diagnostic assay for this important fungal infection, with potential to reduce disease prevalence and improve outcomes.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $976,576 | $0 | |
| Original award | $976,576 | $976,576 |
Quick answers
Who received award R44AI157572?
R44AI157572 was awarded to Pearl Diagnostics, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on March 8, 2021.
How much is award R44AI157572 worth?
$2,929,728 has been obligated on R44AI157572: $1,953,152 in federal funding and $976,576 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award